Autologous Platelet Lysate in Corneal Epithelial Defects

Hanan Jafar

Status and phase: Completed; Phase 2; Phase 1

Conditions: Persistent Corneal Epithelial Defect

Treatments: Biological: Platelet Lysate

Study type: Interventional

Funder types: Other

Identifiers

NCT02979912

PEDUJCTC

Details and patient eligibility

About

Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.

Full description

Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored ideally at -20C and thaw once for use, then will be kept in the refrigerator at +4C, to be taken in multiple doses.

Enrollment: 10 patients

Sex: All

Ages: 21 to 78 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Cognitive ability to understand and sign the consent form.
2. Corneal ulcers that did not re-epithelialise after 1 week of conventional treatment (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic eye-drops).
3. Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy, corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal lesions due to a foreign body.
4. Good compliance with the study regimen and availability for the duration of the entire study period.

Exclusion criteria

1. Corneal ulcers which developed tissue scars.
2. Pregnant or lactating women.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Platelet Lysate

Experimental group

Description:

Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.

Treatment:

Biological: Platelet Lysate